This preclinical study provides a mechanistic understanding of the benefit of combining TOP1 and BRD4 inhibitors to treat pancreatic carcinomas addicted to oncogenic drivers of transcription and replication. The gene discussed is TOP1; the disease is exocrine pancreatic carcinoma.